> top > docs > PMC:7544934 > spans > 4972-5953 > annotations

PMC:7544934 / 4972-5953 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid_Glycan-Motif-Structure

Id Subject Object Predicate Lexical cue
T9 131-134 https://glytoucan.org/Structures/Glycans/G00057MO denotes LDN
T10 131-134 https://glytoucan.org/Structures/Glycans/G31736BK denotes LDN
T11 486-489 https://glytoucan.org/Structures/Glycans/G00057MO denotes LDN
T12 486-489 https://glytoucan.org/Structures/Glycans/G31736BK denotes LDN
T13 594-597 https://glytoucan.org/Structures/Glycans/G00057MO denotes LDN
T14 594-597 https://glytoucan.org/Structures/Glycans/G31736BK denotes LDN
T15 868-871 https://glytoucan.org/Structures/Glycans/G00057MO denotes LDN
T16 868-871 https://glytoucan.org/Structures/Glycans/G31736BK denotes LDN

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
155 517-523 Gene denotes ERK1/2 Gene:5595
156 629-633 Gene denotes ACE2 Gene:59272
157 814-822 Species denotes patients Tax:9606
158 107-117 Chemical denotes naltrexone MESH:D009271
159 272-282 Chemical denotes naltrexone MESH:D009271
160 384-394 Chemical denotes naltrexone MESH:D009271
161 658-666 Disease denotes COVID-19 MESH:C000657245
162 719-728 Disease denotes infection MESH:D007239
163 732-740 Disease denotes COVID-19 MESH:C000657245
164 805-813 Disease denotes COVID-19 MESH:C000657245
165 964-972 Disease denotes COVID-19 MESH:C000657245

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T38 0-267 Sentence denotes In this study, we report that the FDA-approved non-peptide opioid antagonist drug (Vickers & Jolly, 2006), naltrexone in low dose (LDN) suppresses high fat/LPS induced pro-inflammatory cytokine release both from macrophage cells and Adipose tissue macrophages (ATMs).
T39 268-485 Sentence denotes The naltrexone is already an FDA approved drug and thus the pharmacology (pharmacokinetics and pharmacodynamics) of naltrexone is well known and reported elsewhere (Gonzalez & Brogden, 1988; Toljan and Vrooman, 2018).
T40 486-534 Sentence denotes LDN also showed activity as an ERK1/2 inhibitor.
T41 535-643 Sentence denotes Moreover, virtual docking and simulation data also suggest LDN may disrupt the interaction of ACE2 with RBD.
T42 644-981 Sentence denotes As a reliable COVID-19 vaccine is unlikely to available before the maximal infection of COVID-19 has occurred, it is essential to establish therapeutics for the COVID-19 patients, based on our data, we proposed FDA-approved LDN can be used in combination or as an adjuvants therapy to treat mild to moderate symptomatic COVID-19 patients

2_test

Id Subject Object Predicate Lexical cue
32930058-2836152-56195690 453-457 2836152 denotes 1988